Debbie Bechor | Business Development & Communications Manager |
Dror Ben-Asher | Chief Executive Officer |
Rick Scruggs | President and Chief Commercial Officer |
Guy Goldberg | Chief Business Officer |
Gilead Raday | Chief Operating Officer |
Micha Ben-Chorin | Chief Financial Officer |
Adi Frish | Chief Corporate and Business Development Officer |
Rob Jackson | Senior Vice President of Marketing |
Brandon Folkes | Cantor Fitzgerald |
Boobalan Pachaiyappan | H.C. Wainwright |
Matt Kaplan | Ladenburg Thalmann |
Good day, and welcome to RedHill Biopharma's First Quarter 2022 Financial Results and Operational Highlights Conference Call. [Operator Instructions] At this time, I would like to introduce to the conference call RedHill's CEO, Dror Ben-Asher; Rick Scruggs, President of RedHill Biopharma, Inc. and Chief Commercial Officer; Guy Goldberg, Chief Business Officer; Gilead Raday, Chief Operating Officer; Micha Ben-Chorin, Chief Financial Officer; Adi Frish, Chief Corporate and Business Development Officer; and Rob Jackson, Senior Vice President of Marketing.
Before we begin, we will read from RedHill's Safe Harbor statement. Please go ahead.